Physician profile
Lori J Ford
NPI 1740276955
$1,726.38
in general payments reported to CMS, 2019-2025
17 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.55 · 2021: $12.17 · 2022: $14.42 · 2023: $492 · 2024: $92.70 · 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.24 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $725.70 | 2023-2025 | |
| Janssen Biotech, INC. | $274.83 | 2023-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $212.26 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $151.18 | 2025 | Voquezna |
| Lilly USA, LLC | $81.10 | 2025 | Omvoh |
| Genzyme Corporation | $51.44 | 2023-2025 | |
| Pentax of America, INC. | $44.49 | 2024 | Pentax Medical, C2 Cryoballoon Focal Controller, C2 Cryoballoon |
| Regeneron Healthcare Solutions, INC. | $44.15 | 2022-2023 | Dupixent |
| Aimmune Therapeutics, INC. | $20.57 | 2025 | Vowst |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.05 | 2023 | Xifaxan |
| Qol Medical, LLC | $16.71 | 2023 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $15.59 | 2023 | Gattex |
| Medtronic USA, INC. | $15.55 | 2020 | |
| Fresenius Kabi USA, LLC | $14.54 | 2023 | Idacio |
| Celltrion USA INC. | $14.14 | 2025 | Vegzelma |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $13.91 | 2023 | Ocaliva |
| Medtronic, INC. | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.